Progesterone (Progestin-Only Hormone Therapy) in Heterozygous Factor V Leiden
Heterozygous Factor V Leiden is classified as thrombophilia in contraceptive guidance. [1] For progestin-only contraceptives, eligibility depends on the specific formulation, because venous thromboembolism (VTE) risk differs by product. [1]
Medication Selection Algorithm
- Progestin-only pill (POP) (including norethindrone, levonorgestrel-only regimens) should be considered generally usable in heterozygous Factor V Leiden (CDC USMEC Category 2). [1]
- Progestin implant (etonogestrel implant) should be considered generally usable in heterozygous Factor V Leiden (CDC USMEC Category 2). [1]
- Depot medroxyprogesterone acetate (DMPA) should be considered not generally recommended in heterozygous Factor V Leiden (CDC USMEC Category 3). [1]
- Combined estrogen-progestin contraceptives are not addressed in CDC’s POP table and carry a substantially higher VTE risk profile due to estrogen exposure, so these are not treated as equivalent to progesterone-only products. [1]
Key Evidence Supporting This Recommendation
Progestin-only contraceptive use is not consistently associated with increased VTE risk in the general population, based on systematic review evidence. [2] CDC USMEC cites evidence suggesting higher relative risk for VTE with DMPA among women with Factor V Leiden compared with nonusers without the mutation, with the highest relative risk reported for DMPA users. [1]
Monotherapy vs Combination Therapy
Progesterone-only exposure is risk-stratified by formulation, but it is not equivalent to estrogen-containing regimens for VTE risk. [1] Progestin-only approaches (POP or implant) align with “generally usable” classifications in thrombophilia. [1] DMPA aligns with “not generally recommended” classification in thrombophilia due to higher VTE concern relative to other progestin-only methods. [1]
Important Clarifications and Nuances
CDC USMEC addresses contraceptive eligibility categories for progestin-only products. [1] Safety for systemic progesterone used for non-contraceptive indications (for example, abnormal uterine bleeding management or fertility/luteal support) is not specifically resolved by CDC’s progestin-only contraceptive categories. [1]
Initiation Thresholds or Indications
For progestin-only contraception in thrombophilia due to Factor V Leiden, CDC USMEC categorizes: [1]
- Implant: Category 2. [1]
- POP: Category 2. [1]
- DMPA: Category 3. [1]
Common Pitfalls to Avoid
Using DMPA when a lower-risk progestin-only option (POP or implant) is acceptable is a common avoidable mismatch with thrombophilia guidance. [1] Treating all “progesterone/progestin” products as interchangeable for VTE risk is incorrect, because DMPA has product-specific VTE concern in Factor V Leiden cited in CDC guidance. [1]
Targets or Goals of Therapy
The therapeutic goal is effective progestin therapy with selection of a formulation that matches thrombophilia risk category. [1]